CCME Global Ltd
CCME Global Ltd, formerly Genesis IBRC India Ltd and SSK Lifestyles Ltd, is transitioning from a non-operational biotechnology business towards FMCG, commodities, and minerals trading, manufacturing, and import-export activities under new management.[1]
- Market Cap ₹ 187 Cr.
- Current Price ₹ 41.2
- High / Low ₹ 181 / 26.4
- Stock P/E
- Book Value ₹ 7.39
- Dividend Yield 0.00 %
- ROCE %
- ROE -0.31 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 5.58 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Biotechnology
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Sales |
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | |
|---|---|
| 4.33 | |
| Sales growth | |
| 4.15 | |
| Operating Profit | 0.18 |
| OPM % | 4.16% |
| 0.01 | |
| Interest | 0.03 |
| Depreciation | 0.09 |
| Profit before tax | 0.07 |
| Tax % | 128.57% |
| -0.03 | |
| EPS in Rs | -0.02 |
| Dividend Payout % | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 39% |
| 3 Years: | 62% |
| 1 Year: | -78% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 0% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | |
|---|---|
| Equity Capital | 13.00 |
| Reserves | -3.39 |
| 1.48 | |
| 1.21 | |
| Total Liabilities | 12.30 |
| 2.07 | |
| CWIP | 1.30 |
| Investments | 0.00 |
| 8.93 | |
| Total Assets | 12.30 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | |
|---|---|
| 1.68 | |
| -4.66 | |
| 3.00 | |
| Net Cash Flow | 0.02 |
| Free Cash Flow | 1.68 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 933% |
Ratios
Consolidated / View Standalone
| Mar 2018 | |
|---|---|
| Debtor Days | 119.70 |
| Inventory Days | 68.92 |
| Days Payable | 17.87 |
| Cash Conversion Cycle | 170.75 |
| Working Capital Days | 399.56 |
| ROCE % |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Equity Shares Outstanding shares ・Standalone data |
|
|||||||||||
| Promoter Shareholding % ・Standalone data |
||||||||||||
| Number of Shareholders count ・Standalone data |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for Intimation For Holding Board Meeting On November 14, 2026
- Board to meet on November 14, 2026 to approve Q2 and H1 FY2026 unaudited results.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
CCMEGL used to be in the biotechnology
and agri-input (probiotics and aquaculture products) business but has currently transitioned to FMCG, commodities, and minerals trading, etc.